However, the MET gene amplification was particularly notable in this case, considering the recent approval of the c-MET tyrosine kinase inhibitor capmatinib for NSCLC patients based on results from the GEOMETRY mono-1 trial.20 This phase 2 trial described the use of capmatinib in NSCLC patients whose tumors harbored MET exon 14 skipping mutations or were MET-amplified. Here, MET is linked to non-small cell lung carcinoma.